US2020155564A1PendingUtilityA1

Nanoparticulate Meloxicam Formulations

75
Assignee: RECRO PHARMA INCPriority: Mar 3, 2003Filed: Jul 10, 2019Published: May 21, 2020
Est. expiryMar 3, 2023(expired)· nominal 20-yr term from priority
A61K 9/145A61K 9/5169A61K 31/5415A61K 9/10A61K 9/0019A61P 29/00A61K 9/0053A61K 9/5192A61K 9/5138A61K 9/146A61K 9/5123A61K 9/14
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.

Claims

exact text as granted — not AI-modified
1 - 23 . (canceled) 
     
     
         24 . An injectable pharmaceutical dosage form consisting of:
 30 mg of meloxicam, or a salt thereof, wherein the meloxicam is in the form of particles having an effective average particle size of less than about 200 nm;   polyvinylpyrrolidone;   sodium deoxycholate;   sucrose; and   water;   wherein the composition comprises i) no more than 6,000 particles that are greater than 10 μm in size, and ii) no more than 600 particles that are greater than 25 μm in size.   
     
     
         25 . The dosage form of  claim 24 , wherein the effective average particle size of the meloxicam particles, or a salt thereof, is less than about 150 nm. 
     
     
         26 . The dosage form of  claim 24 , wherein the effective average particle size of the meloxicam particles, or a salt thereof, is less than about 100 nm. 
     
     
         27 . The dosage form of  claim 24 , wherein the composition comprises i) no more than 3,000 particles that are greater than 10 μm in size, and ii) no more than 300 particles that are greater than 25 μm in size. 
     
     
         28 . A method of administering meloxicam to a human in need thereof comprising intravenously or intramuscularly injecting the pharmaceutical dosage form of  claim 24  into the human. 
     
     
         29 . The method of  claim 28 , wherein the human has moderate to moderately severe acute pain. 
     
     
         30 . The method of  claim 28 , wherein the pharmaceutical dosage form is administered intravenously to the human. 
     
     
         31 . The method of  claim 28 , wherein the pharmaceutical dosage form is administered intramuscularly to the human. 
     
     
         32 . The method of  claim 28 , wherein the moderate to moderately severe acute pain is low back pain, neck pain, postoperative pain, pain resulting from battle field wounds, dental pain, muscular pain, pain resulting from cancer, headache pain, menstrual cramp pain, abdominal surgery pain, bone manipulation pain, or pain associated with inflammation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.